20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Crinetics Pharmaceuticals Inc (CRNX) operates in the BIOTECHNOLOGY industry and is headquartered in San Diego, United States with about 594 employees. Its market capitalization is roughly $9 billion. In the fiscal year ended 2025-12-31, CRNX reported $8M in revenue and ($465M) in net income.
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Interactive charts & full statements → Open the CRNX valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $42M | $8M | $1M | $4M | $5M | $1M | $0M | $1M | $2M | $2M | $1M |
| Gross Profit | $42M | $7M | $1M | $4M | $5M | $1M | $0M | $1M | $2M | ($7M) | ($5M) |
| Gross Margin % | 100.0% | 86.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -351.5% | -765.9% |
| Operating Income (EBIT) | ($549M) | ($517M) | ($339M) | ($223M) | ($168M) | ($108M) | ($75M) | ($54M) | ($29M) | ($9M) | ($6M) |
| Operating Margin % | -1307.1% | -6714.8% | -32613.5% | -5547.2% | -3544.1% | -9990.9% | -105567.6% | -4512.3% | -1182.5% | -446.3% | -1026.2% |
| Net Income | ($502M) | ($465M) | ($298M) | ($215M) | ($160M) | ($107M) | ($73M) | ($50M) | ($27M) | ($9M) | ($6M) |
| Net Margin % | -1195.2% | -6046.2% | -28720.7% | -5345.9% | -3376.7% | -9899.7% | -102625.4% | -4152.1% | -1116.8% | -447.8% | -1021.9% |
| EBITDA | — | ($461M) | ($296M) | ($213M) | ($167M) | ($107M) | ($74M) | ($53M) | ($28M) | ($9M) | ($6M) |
| Earnings Per Share (EPS) | $-5.06 | $-4.95 | $-3.69 | $-3.69 | $-3.08 | $-2.78 | $-2.39 | $-2.05 | $-2.23 | $-0.66 | $-0.43 |
| Shares Outstanding (M) | — | 94M | 81M | 58M | 52M | 38M | 30M | 24M | 12M | 14M | 14M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $25M | $11M | $6M | $0M | $1M | $0M | $0M | $0M | $0M |
| Gross Profit | $25M | $11M | $6M | $0M | $1M | $0M | ($67M) | ($62M) | $0M |
| Gross Margin % | 100.0% | 98.1% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | 100.0% |
| Operating Income (EBIT) | ($132M) | ($140M) | ($134M) | ($143M) | ($129M) | ($111M) | ($95M) | ($88M) | ($83M) |
| Operating Margin % | -528.0% | -1307.8% | -2169.5% | -99710.5% | -12523.0% | -30860.1% | — | — | -20747.6% |
| Net Income | ($121M) | ($128M) | ($123M) | ($130M) | ($116M) | ($97M) | ($81M) | ($77M) | ($74M) |
| Net Margin % | -484.0% | -1191.0% | -1993.4% | -90972.7% | -11216.0% | -26807.2% | — | — | -18560.1% |
| EBITDA | — | ($127M) | ($122M) | ($129M) | ($115M) | ($96M) | ($80M) | ($76M) | ($73M) |
| Earnings Per Share (EPS) | $-1.14 | $-1.23 | $-1.31 | $-1.38 | $-1.23 | $-1.04 | $-0.88 | $-0.96 | $-0.94 |
| Shares Outstanding (M) | — | 104M | 94M | 94M | 94M | 93M | 91M | 80M | 79M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($423M) | ($378M) | ($226M) | ($166M) | ($115M) | ($89M) | ($62M) | ($46M) | ($19M) | ($9M) | ($5M) |
| Capital Expenditures (CapEx) | $2M | $6M | $4M | $5M | $2M | $0M | $0M | $0M | $1M | $0M | $0M |
| Free Cash Flow (FCF) | ($426M) | ($384M) | ($230M) | ($171M) | ($117M) | ($89M) | ($62M) | ($47M) | ($21M) | ($10M) | ($6M) |
| FCF Margin % | -1014.3% | -4985.5% | -22118.8% | -4261.0% | -2467.0% | -8258.3% | -87623.9% | -3929.0% | -845.1% | -478.4% | -960.6% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($94M) | ($125M) | ($93M) | ($111M) | ($86M) | ($88M) | ($65M) | ($61M) | ($48M) |
| Capital Expenditures (CapEx) | $0M | $1M | $0M | $1M | $3M | $1M | $1M | $1M | $1M |
| Free Cash Flow (FCF) | ($95M) | ($126M) | ($93M) | ($112M) | ($89M) | ($90M) | ($66M) | ($61M) | ($49M) |
| FCF Margin % | -380.0% | -1169.4% | -1515.3% | -78028.7% | -8637.5% | -24845.2% | — | — | -12180.2% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.3B | $1.1B | $1.4B | $635M | $352M | $351M | $183M | $130M | $171M | $16M | $13M |
| Cash & Cash Equivalents | $56M | $102M | $265M | $55M | $33M | $201M | $93M | $40M | $45M | $14M | $12M |
| Total Liabilities | $130M | $143M | $110M | $96M | $36M | $19M | $15M | $13M | $11M | $31M | $19M |
| Total Debt (Short + Long-Term) | — | $6M | $7M | $4M | $1M | $1M | $2M | $1M | $0M | $0M | $0M |
| Total Shareholders' Equity | $1.2B | $992M | $1.3B | $539M | $316M | $332M | $169M | $117M | ($43M) | ($15M) | ($6M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CRNX viewer.
This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी
About TickerBase · Data methodology & sources · Privacy · Terms